4882 — Perseus Proteomics Income Statement
0.000.00%
Last trade - 00:00
- ¥4bn
- ¥2bn
- ¥94m
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 276 | 85.8 | 67.9 | 71.9 | 94.2 |
Cost of Revenue | |||||
Gross Profit | 257 | 79.4 | 64.1 | 67.7 | 86.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 437 | 904 | 481 | 660 | 887 |
Operating Profit | -161 | -818 | -413 | -588 | -793 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -162 | -840 | -411 | -597 | -785 |
Provision for Income Taxes | |||||
Net Income After Taxes | -163 | -842 | -413 | -599 | -787 |
Net Income Before Extraordinary Items | |||||
Net Income | -163 | -842 | -413 | -599 | -787 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -163 | -842 | -413 | -599 | -787 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -13 | -71.7 | -35.3 | -44.6 | -61.6 |
Dividends per Share |